Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 2.68% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Stock is technically in a Bearish range
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Commodity Chemicals
INR 48 Cr (Micro Cap)
NA (Loss Making)
20
0.00%
0.49
-7.84%
3.09
Total Returns (Price + Dividend) 
Shreyas Interm. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Compliances-Reg.24(A)-Annual Secretarial Compliance
30-May-2026 | Source : BSEPursuent the Regulation 24(A) of the SEBI LODR Regulations2015 we enclosed herewith the Secretrial Compliance Report duly issued by Mr. Pankaj Desai PCS for the Financial Year ended March 31 2026.
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations .And Disclosure Requirements) Regulations 2015.
22-May-2026 | Source : BSEShreyas Intermediates Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve In terms of Regulation 29 read with Regulation 30 and 33 of Securities & Exchange Board of India (Listing Obligations and Disclosures) Regulations 2015 this is to inform that the Meeting of the Board of Directors of M/s. Shreyas Intermediates Limited will be held on 28th May 2026 Thursday at the Corporate Office of the Company at 404 Naman Centre C-31 G-Block BKC Bandra East Mumbai 400051 at 04.00 p.m. to consider and approve the followings: 1. To consider and approve Audited Standalone Financial Results for the quarter and year ended 31st March 2026 along with Independent Audit Report thereon 2. Any other items with the permission of Chairman. Further as informed vide our letter dated March 30 2026 the Trading Window for dealing in the securities of the Company was closed from April 01 2026 and shall remain closed till 48 hours after the announcement of financial results by the Board of Directors at its meeting scheduled to be held on May 28 2026.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Apr-2026 | Source : BSEIn terms of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 as amended we are submitting herewith a copy of the certificate received from- Skyline Financial Services Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended 31st March 2026. Kindly place the same on your record.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
10.028
Held by 3 Schemes (0.0%)
Held by 1 FIIs (8.39%)
Kesar Petroproducts Limited (27.59%)
Krish Pharma Speciality Private Limited- Escrow Demat Accoun (24.7%)
7.83%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 0.00% vs -100.00% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 28.21% vs -62.50% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 36.26% vs -8.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 23.62% vs 11.81% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025
YoY Growth in year ended Mar 2026 is 20.75% vs -0.63% in Mar 2025